The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

According to the statistics released by the National Cancer Center in 2024, in 2022, there were 61,000 new cases of ovarian cancers and 33,000 deaths in China.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024.

Siemens Healthineers on Tuesday reported that its revenues rose about 2 percent on a reported basis and 3 percent on a comparable basis during its fiscal second quarter on rising sales of its non-COVID diagnostics products and its advanced therapies products.

Biochemical diagnostic reagents, as one of the main categories of diagnostic reagents, are characterized by a large population coverage, a high proportion of services and service users and a huge market size.

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.

On April 1, Mr. Yu Rong, Chairman of Meinian Onehealth, and his delegation visited the headquarter of Adicon to have a discussion and exchange views on the strategic cooperation and innovative business cooperation between Meinian Onehealth and Adicon.

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2024, which include the consolidated financial results for GRAIL.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal 2024, which ended March 31, 2024.

From April 17 to 26, 2024, Hesheng Wang, Vice Minister of the National Health Commission of the PRC and Director of the National Disease Control and Prevention Administration, led a delegation to visit Germany, Finland and the Republic of Korea.